The pharmacological safety of a combined pharmaceutical composition for the correction of placental dysfunction in pregnant women
Keywords:pharmaceutical safety, pharmaceutical composition, nonfetotoxic active ingredient, placental dysfunction
Topicality. Along with the pronounced pharmacological effectiveness, high requirements for the safety are applied to new medicines. To obtain the necessary information regarding the safety of a potential drug and predict the risk of further side effects, a preclinical study of possible toxic effects, primarily acute toxicity, is performed.
Aim. To study the acute toxicity of a new pharmaceutical composition for the correction of placental dysfunction in pregnant women.
Materials and methods. The study object was the pharmaceutical composition in the form of solid gelatinous capsules containing active pharmaceutical ingredients from basic therapeutic group of drugs used for fetoplacental dysfunction in pregnant women. The acute toxicity was determined according to the methodological guidelines “Preclinical studies of drugs” edited by A. Stefanov, in outbreed female rats weighing 200-250 g in compliance with the “European Convention for the Protection of Vertebrate Animals used for Experimental and other Scientific Purposes” (Strasburg, 1985).
Results and discussion. The study of the pharmaceutical safety has been performed by the acute toxicity criterion under the condition of short-term influence of a new pharmaceutical composition combining the required pharmaceutical ingredients in well-balanced doses affecting different chains of pathogenesis of placental dysfunction. Under the condition of the acute experiment a new combined composition (intraperitoneal introduction in the dose of 5000 mg/kg of the body weight) does not cause changes in the rat’s organism. It has been determined that this pharmaceutical composition belongs to practically nontoxic substances – Toxicity Class V according to the generally accepted classification system.
Conclusions. The data for the preclinical safety assessment of a new combined composition for the correction of placental dysfunction in pregnant women have been obtained.
Korchynska, O. O. et al. (2016). Zdorov’ia natsii, 4 (40), 171–175.
Stasenko, T. (2016). Ukr. med. chasopys, 3 (113), 77–79. Available at: https://www.umj.com.ua/article/96925/zdorov-ya-ditej-zavdannya-vsiyei-medichnoi-spilnoti.
Kustova, S. P. et al. (2020). Pat. № 143079 (UA). MPK (2020.01) A61K 31/44, A61K 9/48, A61R 15/08. Biul., 13, 4.
Stefanov, O. V. (2001). Doklinichni doslidzhennia likarskykh zasobiv. Kyiv: Avitsenna, 528.
Yevropeiska konventsiia pro zakhyst khrebetnykh tvaryn, yaki vykorystovuiutsia dlia doslidnykh ta inshykh naukovykh tsilei: vid 18.03.1986 r. Available at: https://zakon.rada.gov.ua/laws/show/994_137.
Copyright (c) 2020 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).